M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine

Vaccine

Volumn 32, Issue 35, 2014, Pages 4457-4465

  Ye, Ting ^a   Yue, Yan ^a   Fan, Xiangmei ^a   Dong, Chunsheng ^a   Xu, Wei ^a   Xiong, Sidong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Coxsackievirus B3; DNA vaccine; M cell targeting; Mucosal immune response; Viral myocarditis

Indexed keywords

C PEPTIDE; CHITOSAN; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN 30 CHITOSAN PREDOMINANT ANTIGEN VP1 VACCINE; CPE30 PEPTIDE; DEOXYRIBONUCLEASE I; DNA VACCINE; IMMUNOGLOBULIN G; PROTEIN VP1; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COXSACKIE VIRUS B3; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEART PROTECTION; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE; TISSUES; VACCINATION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS MYOCARDITIS; WEIGHT REDUCTION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COXSACKIEVIRUS INFECTIONS; DISEASE MODEL; ENTEROVIRUS; IMMUNOLOGY; MYOCARDITIS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CHITOSAN; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MALE; MICE, INBRED BALB C; MYOCARDITIS; T-LYMPHOCYTES; VACCINES, DNA; VIRAL LOAD; VIRAL VACCINES;

EID: 84904395116     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.050     Document Type: Article

References (43)

1. Kang W., Gomez F.E., Lan J., Sano Y., Ueno C., Kudsk K.A. Parenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin beta receptor expression. Ann Surg 2006, 244:392-399.
2. Gold M.C., Cerri S., Smyk-Pearson S., Cansler M.E., Vogt T.M., Delepine J., et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010, 8:e1000407.
3. + T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 2012, 122:62-69.
4. Salek-Ardakani S., Moutaftsi M., Sette A., Croft M. Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection. J Virol 2011, 85:9051-9059.
5. Pasetti M.F., Simon J.K., Sztein M.B., Levine M.M. Immunology of gut mucosal vaccines. Immunol Rev 2011, 239:125-148.
6. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol Rev 2011, 241:241-259.
7. Pavot V., Rochereau N., Genin C., Verrier B., Paul S. New insights in mucosal vaccine development. Vaccine 2012, 30:142-154.
8. Rhee J.H., Lee S.E., Kim S.Y. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012, 1:50-63.
9. Kraehenbuhl J.P., Neutra M.R. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol 2000, 16:301-332.
10. Kim S.H., Lee K.Y., Jang Y.S. Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination. Immune Netw 2012, 12:165-175.
11. Csaba N., Garcia-Fuentes M., Alonso M.J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Delivery 2006, 3:463-478.
12. Yamamoto M., Pascual D.W., Kiyono H. M cell-targeted mucosal vaccine strategies. Curr Top Microbiol Immunol 2012, 354:39-52.
13. Zlotkowska D., Maddaloni M., Riccardi C., Walters N., Holderness K., Callis G., et al. Loss of sialic acid binding domain redirects protein sigma1 to enhance M cell-directed vaccination. PLoS One 2012, 7:e36182.
14. Lo D., Tynan W., Dickerson J., Scharf M., Cooper J., Byrne D., et al. Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. Int Immunol 2004, 16:91-99.
15. Wang J., Lopez-Fraga M., Rynko A., Lo D.D. TNFR and LTbetaR agonists induce follicle-associated epithelium and M cell specific genes in rat and human intestinal epithelial cells. Cytokine 2009, 47:69-76.
16. Clark R.T., Hope A., Lopez-Fraga M., Schiller N., Lo D.D. Bacterial particle endocytosis by epithelial cells is selective and enhanced by tumor necrosis factor receptor ligands. Clin Vaccine Immunol 2009, 16:397-407.
17. Ling J., Liao H., Clark R., Wong M.S., Lo D.D. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem 2008, 283:30585-30595.
18. Rajapaksa T.E., Stover-Hamer M., Fernandez X., Eckelhoefer H.A. Lo DD. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2010, 142:196-205.
19. Kakutani H., Kondoh M., Fukasaka M., Suzuki H., Hamakubo T., Yagi K. Mucosal vaccination using claudin-4-targeting. Biomaterials 2010, 31:5463-5471.
20. Suzuki H., Kondoh M., Kakutani H., Yamane S., Uchida H., Hamakubo T., et al. The application of an alanine-substituted mutant of the C-terminal fragment of Clostridium perfringens enterotoxin as a mucosal vaccine in mice. Biomaterials 2012, 33:317-324.
21. Lo D.D., Ling J., Eckelhoefer A.H. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol 2012, 12:7.
22. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-391.
23. Wang M., Yue Y., Dong C., Li X., Xu W., Xiong S. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis. Clin Vaccine Immunol 2013, 20:1743-1751.
24. Yue Y., Xu W., Hu L., Jiang Z., Xiong S. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 2009, 386:438-447.
25. Clark M.A., Blair H., Liang L., Brey R.N., Brayden D., Hirst B.H. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 2001, 20:208-217.
26. Tamagawa H., Takahashi I., Furuse M., Yoshitake-Kitano Y., Tsukita S., Ito T., et al. Characteristics of claudin expression in follicle-associated epithelium of Peyer's patches: preferential localization of claudin-4 at the apex of the dome region. Lab Invest 2003, 83:1045-1053.
27. Maddaloni M., Staats H.F., Mierzejewska D., Hoyt T., Robinson A., Callis G., et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 2006, 177:5524-5532.
28. Woodrow K.A., Bennett K.M., Lo D.D. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012, 14:17-46.
29. Kim S.H., Yang I.Y., Jang S.H., Kim J., Truong T.T., Van Pham T., et al. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization. Microb Infect 2013, 15:895-902.
30. D'Souza B., Bhowmik T., Shashidharamurthy R., Oettinger C., Selvaraj P., D'Souza M. Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target 2012, 20:166-173.
31. + T cells. Gastroenterology 2008, 135:917-925.
32. Nochi T., Yuki Y., Matsumura A., Mejima M., Terahara K., Kim D.Y., et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007, 204:2789-2796.
33. Yoo M.K., Kang S.K., Choi J.H., Park I.K., Na H.S., Lee H.C., et al. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010, 31:7738-7747.
34. Gupta P.N., Khatri K., Goyal A.K., Mishra N., Vyas S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007, 15:701-713.
35. Manocha M., Pal P.C., Chitralekha K.T., Thomas B.E., Tripathi V., Gupta S.D., et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005, 23:5599-5617.
36. Suzuki H., Kakutani H., Kondoh M., Watari A., Yagi K. The safety of a mucosal vaccine using the C-terminal fragment of Clostridium perfringens enterotoxin. Pharmazie 2010, 65:766-769.
37. Kim S.H., Seo K.W., Kim J., Lee K.Y., Jang Y.S. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol 2010, 185:5787-5795.
38. Misumi S., Masuyama M., Takamune N., Nakayama D., Mitsumata R., Matsumoto H., et al. Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 2009, 182:6061-6070.
39. Chionh Y.T., Wee J.L., Every A.L., Ng G.Z., Sutton P. M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect Immun 2009, 77:2962-2970.
40. Rynda A., Maddaloni M., Mierzejewska D., Ochoa-Reparaz J., Maslanka T., Crist K., et al. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol 2008, 180:5187-5200.
41. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001, 14:201-207.
42. Bonifacino J.S., Traub L.M. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 2003, 72:395-447.
43. Ivanov A.I., Nusrat A., Parkos C.A. Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. Mol Biol Cell 2004, 15:176-188.